Mandheer Wadhwa
Overview
Explore the profile of Mandheer Wadhwa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stoyas C, Bushart D, Switonski P, Ward J, Alaghatta A, Tang M, et al.
Neuron
. 2019 Dec;
105(4):630-644.e9.
PMID: 31859031
Sirtuin 1 (Sirt1) is a NAD-dependent deacetylase capable of countering age-related neurodegeneration, but the basis of Sirt1 neuroprotection remains elusive. Spinocerebellar ataxia type 7 (SCA7) is an inherited CAG-polyglutamine repeat...
2.
Bennett C, Dastidar S, Ling S, Malik B, Ashe T, Wadhwa M, et al.
Acta Neuropathol
. 2018 May;
136(3):425-443.
PMID: 29725819
Amyotrophic lateral sclerosis type 4 (ALS4) is a rare, early-onset, autosomal dominant form of ALS, characterized by slow disease progression and sparing of respiratory musculature. Dominant, gain-of-function mutations in the...
3.
Shi Y, Bollam S, White S, Laughlin S, Graham G, Wadhwa M, et al.
Dev Cell
. 2016 Nov;
39(4):452-465.
PMID: 27818180
Merlin encoded by the Nf2 gene is a bona fide tumor suppressor that has been implicated in regulation of both the Hippo-Yap and Rac1-Pak1 pathways. Using genetically engineered murine liver...
4.
Sanchez P, Pasrija C, Mulligan M, Wadhwa M, Pratt D, Li T, et al.
Ann Surg
. 2016 Oct;
266(6):1091-1096.
PMID: 27735823
Objective: We aimed to create a reproducible lung injury model utilizing injection of mitochondrial damage-associated molecular products. Our goal was to characterize the pathophysiologic response to damage-associated molecular pattern mediated...
5.
Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, et al.
Sci Signal
. 2014 May;
7(324):ra42.
PMID: 24803537
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival rates and frequently carries oncogenic KRAS mutation. However, KRAS has thus far not been a viable therapeutic target. We...